Fetal pulmonary artery smooth muscle cells (FPASMC)

Fetal pulmonary artery smooth muscle cells (FPASMCs) are the primary contractile components of the pulmonary vasculature in the developing fetus. Their main biological function is to maintain high pulmonary vascular resistance (PVR) in utero, which ensures that only a small fraction of cardiac output enters the non-functional, fluid-filled fetal lungs (Gao and Raj, 2010, American Journal of Physiology-Lung Cellular and Molecular Physiology). At birth, these cells must rapidly transition from a high-tone, proliferative state to a relaxed, quiescent state to allow for the dramatic drop in PVR necessary for neonatal gas exchange. Failure of this physiological transition results in Persistent Pulmonary Hypertension of the Newborn (PPHN), where FPASMCs remain constricted and may undergo pathological hypertrophy and hyperplasia (Steinhorn, 2010, Pediatric Clinics of North America). While FPASMCs are a cell type rather than a single molecular target, they house critical therapeutic targets such as soluble guanylate cyclase, phosphodiesterase enzymes, and endothelin receptors. Clinical management of neonatal pulmonary vascular disease involves using vasodilators like inhaled nitric oxide or sildenafil to target these intracellular pathways, thereby inducing relaxation and improving oxygenation.

Other names

Fetal PASMCPulmonary artery smooth muscle cells (fetal)Neonatal pulmonary artery smooth muscle cells

Pharmacological agents act on molecular targets within these cells to modulate vascular tone; for example, nitric oxide activates soluble guanylate cyclase to increase cGMP, while sildenafil inhibits phosphodiesterase 5 to prevent cGMP degradation, both leading to vasodilation (Abman, 2007, Archives of Disease in Childhood).